Drug Patent Watch

MARCH 16, 2025

The Biosimilar Revolution: How It's Changing the Game for Biologic Drug Manufacturers As the pharmaceutical industry continues to evolve, one trend is gaining significant attention: the rise of biosimilars. In this article, we'll explore the impact of biosimilars on biologic drug life cycle management.

Biosimilars 52

Biosimilars Drugs Marketing Pharmaceuticals 52

BioPharma Drive: Drug Pricing

SEPTEMBER 20, 2023

The drug regulator has twice rejected Alvotech’s biosimilar due to manufacturing issues with a plant in Europe.

Biosimilars 156

Biosimilars FDA Regulations Drugs 156

Drugs.com

FEBRUARY 19, 2025

Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus. WEDNESDAY, Feb. 19, 2025 -- The U.S. Merilog is a rapid-acting human.

Biosimilars 147

Biosimilars FDA Approval FDA Drugs 147

Drug Patent Watch

OCTOBER 17, 2024

Regulatory Considerations for Biosimilar Analytical Similarity Assessments Biosimilars, or follow-on biologics, are biopharmaceuticals that are highly similar to an already approved biological product.

Biosimilars 115

Biosimilars Production 115

BioPharma Drive: Drug Pricing

MAY 13, 2024

As commercial momentum builds, coverage incentives for the Medicare market are expected to favor biosimilars in 2025.

Biosimilars 139

Biosimilars Marketing 139

BioPharma Drive: Drug Pricing

AUGUST 24, 2023

The subsidiary, called Cordavis, will work directly with manufacturers to market or co-produce low-cost biologic drugs, starting with Novartis’ Humira copy.

Biosimilars 243

Biosimilars Drugs Marketing 243

BioPharma Drive: Drug Pricing

JULY 24, 2023

Despite setbacks with a Humira biosimilar, the partners have expanded an existing alliance, with Teva agreeing to purchase bonds while Alvotech pursues a stock sale.

Biosimilars 130

Biosimilars 130

Drug Patent Watch

OCTOBER 16, 2024

Biosimilars, which are biologic drugs that are highly similar to an already approved biologic drug, are transforming the pharmaceutical industry. As patents for original biologic drugs expire, biosimilars are becoming increasingly important, offering more affordable treatment options for patients and healthcare systems.

Biosimilars 115

Biosimilars Drug Development Drugs Pharmaceuticals 115

Drugs.com

FEBRUARY 19, 2025

Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.Merilog is a rapid-acting human. WEDNESDAY, Feb. 19, 2025 -- The U.S.

Biosimilars 130

Biosimilars FDA Approval FDA Drugs 130

BioPharma Drive: Drug Pricing

OCTOBER 2, 2024

It’s the first time, according to the insurer, that this type of model has been used to bring a Humira biosimilar to market, and it yields a much lower cost than both the brand-name version of the drug and biologic copycats.

Biosimilars 130

Biosimilars Marketing Drugs 130

BioPharma Drive: Drug Pricing

OCTOBER 2, 2024

Biosimilar competition to aging blockbusters will erode a large chunk of the pharma giant’s top line over the next few years.

Biosimilars 260

Biosimilars 260

ProRelix Research

JULY 6, 2023

Biosimilar clinical trials and study designs’ Considerations The rising prevalence and large market share of biological products emphasize their importance as treatment options for several cancers and autoimmune diseases. In […] The post Biosimilar clinical trials and study designs’ considerations appeared first on ProRelix Research.

Clinical Trials 105

Clinical Trials Biosimilars Trials Treatment 105

Drug Patent Watch

JULY 9, 2024

The introduction of biosimilars has significantly altered the landscape of biologic drug distribution models. Biosimilars, which are highly similar to […] Source

Biosimilars 104

Biosimilars Drugs 104

Drug Patent Watch

JULY 22, 2024

In the rapidly evolving landscape of biosimilars, intellectual property (IP) strategy is paramount. Biosimilar manufacturers face unique challenges, including navigating […] Source

Biosimilars 105

Biosimilars 105

Drug Patent Watch

DECEMBER 10, 2024

Biosimilars have been transforming the pharmaceutical landscape by offering cost-effective alternatives to biologic drugs. As patents for these biologics expire, the market for biosimilars is expanding rapidly, with significant implications for manufacturing technologies.

Biosimilars 97

Biosimilars Drugs Production Clinical Trials 97

Drug Patent Watch

JULY 11, 2024

In the high-stakes world of biosimilar development, manufacturers are increasingly turning to an unexpected partner: the Patent Trial and Appeal […] Source

Biosimilars 104

Biosimilars Trials 104

Drug Channels

OCTOBER 18, 2022

The biosimilar boom for provider-administered drugs continues to accelerate. Net prices in therapeutic classes with biosimilar competition have declined by 60% or more over the past few years. Some major biological reference products have now lost a majority of their unit sales to their biosimilars. drug distribution.

Biosimilars 97

Biosimilars Drugs Pharmaceuticals Production 97

BioPharma Drive: Drug Pricing

APRIL 19, 2024

The agreement may help Alvotech capitalize on a recent policy shift by CVS that has driven major market share declines for AbbVie’s blockbuster drug.

Biosimilars 183

Biosimilars Marketing Drugs 183

Drug Channels

JULY 18, 2023

The Humira biosimilar market has arrived! This month, nine biosimilar versions of adalimumab launched in the U.S. Surprisingly, two PBMs—Express Scripts and OptumRx—will each offer at least one low-list-price biosimilar option on their main national formularies.

Biosimilars 98

Biosimilars Pharmacy Marketing Drugs 98

Drug Channels

OCTOBER 3, 2023

Since I published the article below in July 2023 , there have been three notable market develpoments: IQVIA has reported that as as of mid-2023, there was almost no adoption of Amgen's Amjevita, the first Humira biosimilar. Boehringer-Ingelheim launched an unbranded, low WAC version of its interchangeable biosimilar.

Biosimilars 98

Biosimilars Pharmacy Marketing Pharmaceuticals 98

Drug Channels

SEPTEMBER 7, 2022

As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. In many therapeutic areas, biosimilars’ market share is approaching 80%. will face multiple biosimilar competitors. Prices are dropping while adoption accelerates. I also offer some thoughts on 2023 and 2024.

Biosimilars 98

Biosimilars Marketing Drugs Production 98

Drug Patent Watch

NOVEMBER 20, 2024

The pharmaceutical industry is constantly evolving, and one of the most exciting areas of growth is the development of biosimilars. These biological products, designed to be highly similar to existing approved biologics, offer the promise of more affordable treatment options for patients.

Biosimilars 98

Biosimilars Pharmaceuticals Treatment Production 98

Drug Patent Watch

AUGUST 15, 2023

A recent paper in Expert Opinion on Biological Therapy studies failed fillings for biosimilar drugs.

Biosimilars 98

Biosimilars Therapies Treatment Disease 98

BioPharma Drive: Drug Pricing

APRIL 26, 2024

Prescription volume erosion is tracking with company forecasts, executives claimed, even as more insurers could exclude the branded drug.

Biosimilars 171

Biosimilars Drugs 171

BioPharma Drive: Drug Pricing

JULY 18, 2024

The German drugmaker will offer a 92% discount on a copycat version of Humira for people who pay cash for the drug through GoodRx.

Biosimilars 177

Biosimilars Drugs 177

BioPharma Drive: Drug Pricing

JULY 26, 2024

Glycomimetics and Cue Biopharma both revealed layoffs. Elsewhere, AbbVie’s earnings impressed Wall Street and an FDA panel recommended changing testing requirements for some lung cancer drugs.

Biosimilars 156

Biosimilars FDA Drugs 156

Drug Patent Watch

MARCH 31, 2024

A recent study published in JAMA Health Forum sheds light on the impact of biosimilar competition on patient out-of-pocket (OOP) costs for biologic drugs in the United States. The research,… Source

Biosimilars 105

Biosimilars Drugs Research 105

Drug Channels

FEBRUARY 7, 2023

As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. Its strategy echoes the pricing of the first interchangeable insulin biosimilars— as I predicted in 2021. Unfortunately, we should expect most PBMs and plan sponsors to embrace the high-list/high-rebate version.

Biosimilars 98

Biosimilars Drugs Production Marketing 98

Drug Channels

JANUARY 10, 2023

Below, I highlight four takeaways from this year’s lists, including a look at biosimilar insulin and the forthcoming biosimilar competition for Humira. Growth in the number of excluded drugs slowed for the second year, due partly to the fact that so many drugs have already been dropped from PBMs’ formularies.

Biosimilars 98

Biosimilars Pharmacy Drugs Production 98

Drug Patent Watch

FEBRUARY 3, 2021

Abstract Biosimilar medicines expand the biotherapeutic market and improve…. The post The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA appeared first on DrugPatentWatch - Make Better Decisions.

Biosimilars 98

Biosimilars FDA Licensing Licensing 98

Drug Channels

JANUARY 28, 2022

Fiza discusses the impending influx of biosimilars and its effect on manufacturers, specifically in the immunology space. To learn more, sign up for MMIT’s Immunology Biosimilars webcast. Today’s guest post comes from Fiza Bari, Senior Solutions Consultant and GTM Liaison at MMIT.

Biosimilars 98

Biosimilars Marketing Drugs 98

Drug Channels

MARCH 28, 2023

Below, I highlight four takeaways from this year’s lists, including a look at biosimilar insulin and the forthcoming biosimilar competition for Humira. Growth in the number of excluded drugs slowed for the second year, due partly to the fact that so many drugs have already been dropped from PBMs’ formularies.

Biosimilars 98

Biosimilars Pharmacy Drugs Production 98

BioPharma Drive: Drug Pricing

APRIL 5, 2024

The German pharmaceutical company is “streamlining” its custom-facing teams behind Cyltezo, a copycat version of AbbVie’s immune disease drug Humira.

Biosimilars 156

Biosimilars Pharmaceutical Companies Pharmaceuticals Disease 156

Drug Channels

JANUARY 9, 2024

This year, Humira and its 13 biosimilars will provide the most intriguing formulary drama. Unfortunately, the gross-to-net bubble will remain a fixture for this category, despite a price war led by almost half of the biosimilars.

Biosimilars 98

Biosimilars Pharmacy Production Drugs 98

BioPharma Drive: Drug Pricing

JANUARY 22, 2024

The divestment, which includes sales and reimbursement staff, is part of Coherus plan to shift resources toward its R&D work in oncology.

Biosimilars 164

Biosimilars 164

Drug Channels

OCTOBER 14, 2022

Steve walks us through the expected Humira biosimilars launches and discusses potential responses from payers. Today’s guest post comes from Steve Callahan, Senior Manager of Market Research at MMIT. To learn more, check out MMIT’s Strategic Launch Report & Evaluate Forecast solution. Read on for Steve’s insights.

Biosimilars 98

Biosimilars Pharma Companies Marketing Research 98

BioPharma Drive: Drug Pricing

MAY 22, 2024

Today’s rundown also includes news of an expanded partnership for Boehringer Ingelheim and updates to emerging medicines from GSK and Bristol Myers.

Biosimilars 164

Biosimilars 164